Global healthcare

October 5, 2021

Tecartus Granted New Leukemia Indication

October 5, 2021 – Tecartus® (brexucabtagene autoleucel) has received a new indication to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia in adults